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Purpose
To assess the appropriateness of ibutilide use and to identify 
opportunities for optimal patient selection and monitoring per 
the FDA label and BHSF ibutilide protocol/orders
Retrospective chart review of patients treated with ibutilide for 
pharmacologic cardioversion
Armando Mieres Pharm.D. Candidate; Caneel Marrero Pharm.D. Candidate; Joyce Lee, Pharm.D., BCCCP; Radhan Gopalani, Pharm.D., BCPS; 
Faaria Quadri, Pharm.D., BCPS; Baptist Hospital of Miami, Department of Pharmacy; Miami, FL
• Atrial fibrillation (AF) is the most common cardiac 
arrhythmia
• Ibutilide is a class III antiarrhythmic agent used to restore
normal sinus rhythm (NSR) in patients with AF and atrial
flutter (AFL)
• Compared to other antiarrhythmic agents, ibutilide has 
demonstrated similar or superior efficacy in clinical trials
• Its use in AF and AFL is supported by guidelines with a class 
1A recommendation
• Risks associated with ibutilide include QT interval 
prolongation and torsades de pointes, especially in patients 
with electrolyte imbalances
• A protocol for pharmacologic cardioversion has been 
established to facilitate safety and efficacy of ibutilide within 
Baptist Health South Florida (BHSF) hospitals
Background Results Discussion
• Ibutilide use at BHSF is consistent with current guidelines
• Paroxysmal AF and AFL were more likely to convert to NSR 
with ibutilide
• Opportunities for improvement:
• Baseline electrolyte monitoring and replacement prior to 
ibutilide administration
• Documentation of QT intervals
• Staff education to enhance compliance with the 
established pharmacologic cardioversion protocol may 
further improve effectiveness and ensure safety of 
ibutilide in AF patients
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Conclusion
• Majority of patients (54/63) received ibutilide for 
cardioversion of AF
• Forty-four (69.8%) with paroxysmal AF and 10 (15.9%) 
with persistent AF
• Overall, 70% of patients successfully converted to NSR, 
requiring an average of 1.6 doses per patient
• 17/44 patients required two doses for conversion to NSR
• Baseline hypokalemia or hypomagnesemia was noted in 
13/56 patients
• Only 10/13 had electrolytes replenished
• Although all patient were on continuous telemetry monitor, 
not all had QT interval consistently documented
• QT prolongation was noted in 10 patients post-ibutilide, 
with 2/10 patients missing a baseline magnesium level
• All patients (30/30) with CHA2DS2-VASc score of ≥ 2 were 
prescribed anticoagulation therapy upon discharge
Limitations
• Small sample size
• Inconsistent documentation of QT interval




• Multicenter, retrospective chart review
• Per BHSF IRB, this review does not constitute human 
subjects research
• Inclusion Criteria
• Age ≥ 18 years
• Administration of ibutilide between June 1st, 2018 and 
May 24th, 2019
• Exclusion Criteria:  None
• Primary Endpoint
• Incidence of successful conversion to NSR
• Secondary Endpoints
• Electrolyte monitoring and replacement
• Incidence of QT interval prolongation (QT interval ≥ 450 
milliseconds)
• Anticoagulation therapy based on CHA2DS2-VASc score
Secondary Endpoints
Electrolyte Management, n (%)
• Electrolyte monitoring                                                         56/63 (89)
• Required electrolyte replacement   13/56 (23.2) 
• Received electrolyte replacement    10/13 (76.9)
QT Prolongation Post-Ibutilide, n (%)                                        10 (15.9)
Anticoagulation Therapy, n (%)
• CHA2DS2-VASc score of ≥ 2                                        30 (47.6)















Paroxysmal AF 36/44 (82)





Baseline Characteristics           N = 63
Demographics
Mean age (range), years 7 (19 - 91)
Mean weight (range), kg             93 (48 - 142)
Male, n (%)                                   45 (71.4)
Arrhythmia for > 48 hr, n (%)                          19 (30.2)
Treatment Setting, n (%)
Emergency Department                              






Paroxysmal Atrial Fibrillation 44 (69.8)
Persistent Atrial Fibrillation 10 (15.9)
Atrial Flutter                                             8 (12.7)
Persistent Atrial Tachycardia            1 (1.6)
Ibutilide Doses Administered, n (%)
One                                                                  40 (46.5)               
Two                                                                  23 (26.7)
